In conclusion, we designed, produced and evaluated a novel anti-B7-H3 cytotoxic affibody-drug conjugate (AfDC) that, from these preliminary in vitro data, shows high potential for translation to the therapy of AML, warranting further preclinical and translational exploration, including pharmacokinetic and in vivo efficacy studies. This evidence concerns the gene CD276 and acute myeloid leukemia.